
Intratumoral Cancer Therapy Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Company Analysis
Description
Intratumoral Cancer Therapy Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Company Analysis
Global Intratumoral Cancer Therapy Market will reach US$ 212.92 Billion by 2027. As per Globocan statistics Worldwide, cancer is the highest cause of death; with 19,292,789 new cancer cases were diagnosed and around 9,958,133 cancer death happened in the year 2020. Nevertheless, over the past years, the treatment paradigm of cancer has transformed with several therapies such as radiation therapies, chemotherapies, and immunotherapies available to treat cancer. Correspondingly, intratumoral immunotherapy is a cancer treatment that improves the immune system's ability to fight cancer. This therapy is preferable to the old technique because it provides long-term cancer protection, has fewer side effects, and treats a broader range of cancer.
Impact of COVID-19 on Intratumoral Cancer Therapy Industry:
COVID-19 had a mixed impact on the intratumoral cancer therapy industry. Due to the lockdown restrictions and travel ban, it was difficult for the patients to get the therapy done. In the COVID- 19, there is a high chance for cancer patients to get infected because COVID 19 affects the patient's immune systems. However, continuous cancer intratumoral treatment processes for cancer patients are mandatory, and it enhances their immune system's ability to fight against COVID. Intratumoral therapy is a cancer treatment that boosts the human immune system to fight against cancer cells. Further, cancer patients require regular monitoring of the conditions, resulting in industry growth.
Although many factors propel the growth of the global intratumoral cancer therapy market, such as an increase in healthcare expenditure, a surge in access to medical insurance, a rise in the incidence of cancer, and a rise in technological advancements in cancer treatment therapies. According to Renub Research report, the Worldwide Intratumoral Cancer Therapy Market Size was US$ 111.41 Billion in 2021.
Global Intratumoral Cancer Therapy Industry will grow at a CAGR of 11.4% from 2021-2027
Based on technology, the intratumoral cancer therapy industry includes Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immune System Modulators, Adoptive Cell Transfer, Cytokines, and Others. The monoclonal antibody technology has the most significant growth in the previous year, owing to a surge in monoclonal antibodies for cancer immunotherapy. They exhibit different properties where the immune technique can be modulated, and thus they can activate or inhibit the molecules targeted on the immune system. Additionally, monoclonal antibodies also generate the antitumor immune response. There are various monoclonal antibodies, such as naked, conjugated, and bispecific monoclonal antibodies.
In terms of application, cancer intratumoral therapy is used to treat various cancer applications like Colorectal Cancer, Melanoma, Prostate Cancer, Lung Cancer, Breast Cancer, Head & Neck Cancer, and others. Lungs cancer had the most consequential market. Owing to the high incidence of lung cancer globally and the surge in the awareness program regarding the need for early lung cancer therapeutics. The U.S. food and drug administration has authorized Tabrecta (Capmatinib) to regale non-small cell lung cancer in 2020.
North America holds a Considerable Cancer Intratumoral Therapy Market Worldwide
Geographically, North America held a considerable global cancer intratumoral therapy market. Rising accessibility to current therapy and increasing cancer disease incidence, combined with a growing senior population, lead to regional market development. Recently, U.S. food and administration has supported 32 various immunotherapies to treat 20 cancer diseases, including immunomodulators, cell-based immunotherapies, BCG vaccines, targeted therapies, and oncotic viruses.
The Asia Pacific is to experience the fastest growth owing to a rise in healthcare expenditure, the surge in per capita income, and improvement in healthcare infrastructure. Countries like China and Japan are introducing new and sophisticated immunotherapy medications. These countries have clinical trials for new drug molecules, alternative treatments, and FDA approval.
Key Market Players:
The major players operating in the global intratumoral cancer therapy market include Amgen Inc, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc, Novarts AG, Johnson & Johnson, Eli Lily Company, F. Hoffmann-la Roche Ltd, Seattle Genetics Inc.
Renub Research report titled “Intratumoral Cancer Therapy Market, Global Forecast, by Application (Colorectal Cancer, Melanoma, Prostate Cancer, Lung Cancer, Breast Cancer, Head & Neck Cancer, and others), Technology Type (Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immune System Modulators, Adoptive Cell Transfer, Cytokines, and Others), End Users (Hospital, Cancer Research Centres, Clinical), Regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Company Analysis (Amgen Inc, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc, Novarts AG, Johnson & Johnson, Eli Lily Company, F. Hoffmann-la Roche Ltd, Seattle Genetics Inc)” provides a complete analysis of Global Intratumoral Cancer Therapy Industry
Application - Market has been covered from 7 viewpoints
1. Lung Cancer
2. Breast Cancer
3. Colorectal Cancer
4. Melanoma
5. Prostate Cancer
6. Head & Neck Cancer
7. Others
Technology Type - Market has been covered from 6 viewpoints
1. Monoclonal Antibodies
2. Vaccines
3. Checkpoint Inhibitors
4. Cell Therapies
5. Immune System Modulators
6. Adoptive Cell Transfer
7. Cytokines
8. Others
End Users - Market has been covered from 3 viewpoints
1. Hospital
2. Cancer Research Centres
3. Clinical
Regions - Market has been covered from 5 viewpoints
1. North America
2. Europe
3. Asia Pacific
4. Latin America
5. Middle East & Africa
Company Insights:
• Overview
• Initiatives & Strategy
• Revenue
Companies Covered in the Report:
1. Amgen Inc
2. AstraZeneca
3. Bayer AG
4. Bristol-Myers Squibb Company
5. Pfizer Inc
6. Novarts AG
7. Johnson & Johnson
8. Eli Lily Company
9. F. Hoffmann-la Roche Ltd
10. Seattle Genetics Inc
Global Intratumoral Cancer Therapy Market will reach US$ 212.92 Billion by 2027. As per Globocan statistics Worldwide, cancer is the highest cause of death; with 19,292,789 new cancer cases were diagnosed and around 9,958,133 cancer death happened in the year 2020. Nevertheless, over the past years, the treatment paradigm of cancer has transformed with several therapies such as radiation therapies, chemotherapies, and immunotherapies available to treat cancer. Correspondingly, intratumoral immunotherapy is a cancer treatment that improves the immune system's ability to fight cancer. This therapy is preferable to the old technique because it provides long-term cancer protection, has fewer side effects, and treats a broader range of cancer.
Impact of COVID-19 on Intratumoral Cancer Therapy Industry:
COVID-19 had a mixed impact on the intratumoral cancer therapy industry. Due to the lockdown restrictions and travel ban, it was difficult for the patients to get the therapy done. In the COVID- 19, there is a high chance for cancer patients to get infected because COVID 19 affects the patient's immune systems. However, continuous cancer intratumoral treatment processes for cancer patients are mandatory, and it enhances their immune system's ability to fight against COVID. Intratumoral therapy is a cancer treatment that boosts the human immune system to fight against cancer cells. Further, cancer patients require regular monitoring of the conditions, resulting in industry growth.
Although many factors propel the growth of the global intratumoral cancer therapy market, such as an increase in healthcare expenditure, a surge in access to medical insurance, a rise in the incidence of cancer, and a rise in technological advancements in cancer treatment therapies. According to Renub Research report, the Worldwide Intratumoral Cancer Therapy Market Size was US$ 111.41 Billion in 2021.
Global Intratumoral Cancer Therapy Industry will grow at a CAGR of 11.4% from 2021-2027
Based on technology, the intratumoral cancer therapy industry includes Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immune System Modulators, Adoptive Cell Transfer, Cytokines, and Others. The monoclonal antibody technology has the most significant growth in the previous year, owing to a surge in monoclonal antibodies for cancer immunotherapy. They exhibit different properties where the immune technique can be modulated, and thus they can activate or inhibit the molecules targeted on the immune system. Additionally, monoclonal antibodies also generate the antitumor immune response. There are various monoclonal antibodies, such as naked, conjugated, and bispecific monoclonal antibodies.
In terms of application, cancer intratumoral therapy is used to treat various cancer applications like Colorectal Cancer, Melanoma, Prostate Cancer, Lung Cancer, Breast Cancer, Head & Neck Cancer, and others. Lungs cancer had the most consequential market. Owing to the high incidence of lung cancer globally and the surge in the awareness program regarding the need for early lung cancer therapeutics. The U.S. food and drug administration has authorized Tabrecta (Capmatinib) to regale non-small cell lung cancer in 2020.
North America holds a Considerable Cancer Intratumoral Therapy Market Worldwide
Geographically, North America held a considerable global cancer intratumoral therapy market. Rising accessibility to current therapy and increasing cancer disease incidence, combined with a growing senior population, lead to regional market development. Recently, U.S. food and administration has supported 32 various immunotherapies to treat 20 cancer diseases, including immunomodulators, cell-based immunotherapies, BCG vaccines, targeted therapies, and oncotic viruses.
The Asia Pacific is to experience the fastest growth owing to a rise in healthcare expenditure, the surge in per capita income, and improvement in healthcare infrastructure. Countries like China and Japan are introducing new and sophisticated immunotherapy medications. These countries have clinical trials for new drug molecules, alternative treatments, and FDA approval.
Key Market Players:
The major players operating in the global intratumoral cancer therapy market include Amgen Inc, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc, Novarts AG, Johnson & Johnson, Eli Lily Company, F. Hoffmann-la Roche Ltd, Seattle Genetics Inc.
Renub Research report titled “Intratumoral Cancer Therapy Market, Global Forecast, by Application (Colorectal Cancer, Melanoma, Prostate Cancer, Lung Cancer, Breast Cancer, Head & Neck Cancer, and others), Technology Type (Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immune System Modulators, Adoptive Cell Transfer, Cytokines, and Others), End Users (Hospital, Cancer Research Centres, Clinical), Regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Company Analysis (Amgen Inc, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc, Novarts AG, Johnson & Johnson, Eli Lily Company, F. Hoffmann-la Roche Ltd, Seattle Genetics Inc)” provides a complete analysis of Global Intratumoral Cancer Therapy Industry
Application - Market has been covered from 7 viewpoints
1. Lung Cancer
2. Breast Cancer
3. Colorectal Cancer
4. Melanoma
5. Prostate Cancer
6. Head & Neck Cancer
7. Others
Technology Type - Market has been covered from 6 viewpoints
1. Monoclonal Antibodies
2. Vaccines
3. Checkpoint Inhibitors
4. Cell Therapies
5. Immune System Modulators
6. Adoptive Cell Transfer
7. Cytokines
8. Others
End Users - Market has been covered from 3 viewpoints
1. Hospital
2. Cancer Research Centres
3. Clinical
Regions - Market has been covered from 5 viewpoints
1. North America
2. Europe
3. Asia Pacific
4. Latin America
5. Middle East & Africa
Company Insights:
• Overview
• Initiatives & Strategy
• Revenue
Companies Covered in the Report:
1. Amgen Inc
2. AstraZeneca
3. Bayer AG
4. Bristol-Myers Squibb Company
5. Pfizer Inc
6. Novarts AG
7. Johnson & Johnson
8. Eli Lily Company
9. F. Hoffmann-la Roche Ltd
10. Seattle Genetics Inc
Table of Contents
172 Pages
- 1. Introduction
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Dynamics
- 4.1 Drivers
- 4.2 Restraints
- 5. Global Intratumoral Cancer Therapy Market
- 6. Market Share Analysis - Global Intratumoral Cancer Therapy Market
- 6.1 By Application
- 6.2 Technology Type
- 6.3 By End User
- 6.4 By Regions
- 7. Application - Global Intratumoral Cancer Therapy Market
- 7.1 Lung Cancer
- 7.2 Breast Cancer
- 7.3 Colorectal Cancer
- 7.4 Melanoma
- 7.5 Prostate Cancer
- 7.6 Head & Neck Cancer
- 7.7 Others
- 8. Technology Type - Global Intratumoral Cancer Therapy Market
- 8.1 Monoclonal Antibodies
- 8.2 Vaccines
- 8.3 Checkpoint Inhibitors
- 8.4 Cell Therapies
- 8.5 Immune System Modulators
- 8.6 Adoptive Cell Transfer
- 8.7 Cytokines
- 8.8 Others
- 9. End Users - Global Intratumoral Cancer Therapy Market
- 9.1 Hospital
- 9.2 Cancer Research Centres
- 9.3 Clinica
- 10. Regions - Global Intratumoral Cancer Therapy Market
- 10.1 North America
- 10.2 Europe
- 10.3 Asia Pacific
- 10.4 Latin America
- 10.5 Middle East & Africa
- 11. Porters Five Forces
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
- 12. Company Analysis – Global Intratumoral Cancer Therapy Market
- 12.1 Amgen Inc.
- 12.1.1 Overview
- 12.1.2 Initiatives & Strategy
- 12.1.3 Revenue
- 12.2 AstraZeneca
- 12.2.1 Overview
- 12.2.2 Initiatives & Strategy
- 12.2.3 Revenue
- 12.3 Bayer AG
- 12.3.1 Overview
- 12.3.2 Initiatives & Strategy
- 12.3.3 Revenue
- 12.4 Bristol-Myers Squibb Comapny
- 12.4.1 Overview
- 12.4.2 Initiatives & Strategy
- 12.4.3 Revenue
- 12.5 Pfizer Inc
- 12.5.1 Overview
- 12.5.2 Initiatives & Strategy
- 12.5.3 Revenue
- 12.6 Novarts AG
- 12.6.1 Overview
- 12.6.2 Initiatives & Strategy
- 12.6.3 Revenue
- 12.7 Johnson & Johnson
- 12.7.1 Overview
- 12.7.2 Initiatives & Strategy
- 12.7.3 Revenue
- 12.8 Eli Lily Comapny
- 12.8.1 Overview
- 12.8.2 Initiatives & Strategy
- 12.8.3 Revenue
- 12.9 F. Hoffmann-la Roche Ltd
- 12.9.1 Overview
- 12.9.2 Initiatives & Strategy
- 12.9.3 Revenue
- 12.10 Seattle Genetics Inc
- 12.10.1 Overview
- 12.10.2 Initiatives & Strategy
- 12.10.3 Revenue
- List Of Figures:
- Figure-01: Global – Intratumoral Cancer Therapy Market (Billion US$), 2017 – 2021
- Figure-02: Global – Forecast for Intratumoral Cancer Therapy Market (Billion US$), 2022 – 2027
- Figure-03: Application – Lung Cancer Market (Billion US$), 2017 – 2021
- Figure-04: Application – Forecast for Lung Cancer Market (Billion US$), 2022 – 2027
- Figure-05: Application – Breast Cancer Market (Billion US$), 2017 – 2021
- Figure-06: Application – Forecast for Breast Cancer Market (Billion US$), 2022 – 2027
- Figure-07: Application – Colorectal Cancer Market (Billion US$), 2017 – 2021
- Figure-08: Application – Forecast for Colorectal Cancer Market (Billion US$), 2022 – 2027
- Figure-09: Application – Melanoma Market (Billion US$), 2017 – 2021
- Figure-10: Application – Forecast for Melanoma Market (Billion US$), 2022 – 2027
- Figure-11: Application – Prostate Cancer Market (Billion US$), 2017 – 2021
- Figure-12: Application – Forecast for Prostate Cancer Market (Billion US$), 2022 – 2027
- Figure-13: Application – Head & Neck Cancer Market (Billion US$), 2017 – 2021
- Figure-14: Application – Forecast for Head & Neck Cancer Market (Billion US$), 2022 – 2027
- Figure-15: Application – Others Market (Billion US$), 2017 – 2021
- Figure-16: Application – Forecast for Others Market (Billion US$), 2022 – 2027
- Figure-17: Technology Type – Monoclonal Antibodies Market (Billion US$), 2017 – 2021
- Figure-18: Technology Type – Forecast for Monoclonal Antibodies Market (Billion US$), 2022 – 2027
- Figure-19: Technology Type – Vaccines Market (Billion US$), 2017 – 2021
- Figure-20: Technology Type – Forecast for Vaccines Market (Billion US$), 2022 – 2027
- Figure-21: Technology Type – Checkpoint Inhibitors Market (Billion US$), 2017 – 2021
- Figure-22: Technology Type – Forecast for Checkpoint Inhibitors Market (Billion US$), 2022 – 2027
- Figure-23: Technology Type – Cell Therapies Market (Billion US$), 2017 – 2021
- Figure-24: Technology Type – Forecast for Cell Therapies Market (Billion US$), 2022 – 2027
- Figure-25: Technology Type – Immune System Modulators Market (Billion US$), 2017 – 2021
- Figure-26: Technology Type – Forecast for Immune System Modulators Market (Billion US$), 2022 – 2027
- Figure-27: Technology Type – Adoptive Cell Transfer Market (Billion US$), 2017 – 2021
- Figure-28: Technology Type – Forecast for Adoptive Cell Transfer Market (Billion US$), 2022 – 2027
- Figure-29: Technology Type – Cytokines Market (Billion US$), 2017 – 2021
- Figure-30: Technology Type – Forecast for Cytokines Market (Billion US$), 2022 – 2027
- Figure-31: Technology Type – Others Market (Billion US$), 2017 – 2021
- Figure-32: Technology Type – Forecast for Others Market (Billion US$), 2022 – 2027
- Figure-33: End User – Hospital Market (Billion US$), 2017 – 2021
- Figure-34: End User – Forecast for Hospital Market (Billion US$), 2022 – 2027
- Figure-35: End User – Cancer Research Centres Market (Billion US$), 2017 – 2021
- Figure-36: End User – Forecast for Cancer Research Centres Market (Billion US$), 2022 – 2027
- Figure-37: End User – Clinical Market (Million US$), 2017 – 2021
- Figure-38: End User – Forecast for Clinical Market (Million US$), 2022 – 2027
- Figure-39: North America – Intratumoral Cancer Therapy Market (Billion US$), 2017 – 2021
- Figure-40: North America – Forecast for Intratumoral Cancer Therapy Market (Billion US$), 2022 – 2027
- Figure-41: Europe – Intratumoral Cancer Therapy Market (Million US$), 2017 – 2021
- Figure-42: Europe – Forecast for Intratumoral Cancer Therapy Market (Million US$), 2022 – 2027
- Figure-43: Asia Pacific – Intratumoral Cancer Therapy Market (Billion US$), 2017 – 2021
- Figure-44: Asia Pacific – Forecast for Intratumoral Cancer Therapy Market (Billion US$), 2022 – 2027
- Figure-45: Latin America – Intratumoral Cancer Therapy Market (Billion US$), 2017 – 2021
- Figure-46: Latin America – Forecast for Intratumoral Cancer Therapy Market (Billion US$), 2022 – 2027
- Figure-47: Middle East & Africa – Intratumoral Cancer Therapy Market (Million US$), 2017 – 2021
- Figure-48: Middle East & Africa – Forecast for Intratumoral Cancer Therapy Market (Million US$), 2022 – 2027
- Figure-49: Amgen Inc. – Global Revenue (Million US$), 2017 – 2021
- Figure-50: Amgen Inc. – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-51: AstraZeneca – Global Revenue (Million US$), 2017 – 2021
- Figure-52: AstraZeneca – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-53: Bayer AG – Global Revenue (Million US$), 2017 – 2021
- Figure-54: Bayer AG – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-55: Bristol-Myers Squibb Comapny – Global Revenue (Million US$), 2017 – 2021
- Figure-56: Bristol-Myers Squibb Comapny – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-57: Pfizer Inc – Global Revenue (Million US$), 2017 – 2021
- Figure-58: Pfizer Inc – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-59: Novarts AG – Global Revenue (Million US$), 2017 – 2021
- Figure-60: Novarts AG – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-61: Johnson & Johnson – Global Revenue (Million US$), 2017 – 2021
- Figure-62: Johnson & Johnson – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-63: Eli Lily Comapny – Global Revenue (Million US$), 2017 – 2021
- Figure-64: Eli Lily Comapny – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-65: F. Hoffmann-la Roche Ltd – Global Revenue (Million US$), 2017 – 2021
- Figure-66: F. Hoffmann-la Roche Ltd – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-67: Seattle Genetics Inc – Global Revenue (Million US$), 2017 – 2021
- Figure-68: Seattle Genetics Inc – Forecast for Global Revenue (Million US$), 2022 – 2027
- List Of Tables:
- Table-01: Global – Intratumoral Cancer Therapy Market Share by Application (Percent), 2017 – 2021
- Table-02: Global – Forecast for Intratumoral Cancer Therapy Market Share by Application (Percent), 2022 – 2027
- Table-03: Global – Intratumoral Cancer Therapy Market Share by Technology Type (Percent), 2017 – 2021
- Table-04: Global – Forecast for Intratumoral Cancer Therapy Market Share by Technology Type (Percent), 2022 – 2027
- Table-05: Global – Intratumoral Cancer Therapy Market Share by End User (Percent), 2017 – 2021
- Table-06: Global – Forecast for Intratumoral Cancer Therapy Market Share by End User (Percent), 2022 – 2027
- Table-07: Global – Intratumoral Cancer Therapy Market Share by Region (Percent), 2017 – 2021
- Table-08: Global – Forecast for Intratumoral Cancer Therapy Market Share by Region (Percent), 2022 – 2027
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.